ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 888

Role of Calcium/Calmodulin Kinase IV On Podocyte Function in Lupus Nephritis

Kunihiro Ichinose1, Takeshi Ushigusa2, Tomohiro Koga3, George C. Tsokos4 and Atsushi Kawakami5, 1Department of Immunology and Rheumatology, Unit of Translational Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 2Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 3Medicine/Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 4Medicine/Rheumatology, BIDMC, Harvard Medical School, Boston, MA, 5Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Kidney, lupus nephritis and pathogenesis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Human Etiology and Pathogenesis I

Session Type: Abstract Submissions (ACR)

Role of calcium/calmodulin kinase IV on podocyte function in lupus nephritis

Background/Purpose: Kidney podocytes and their slit diaphragms settle the integrity of renal basement membrane and prevent urinary protein loss.  T cell from patients with systemic lupus erythematosus display increased expression of calcium/calmodulin kinase IV (CaMKIV).  Here we evaluated the expression of CaMKIV in kidney biopsy specimens from patients with lupus nephritis (LN) and in a human podocyte cell line (AB8/13) after exposure to IgG from sera of patients with LN

Methods: We examined the expression level of nephrin, a podocyte marker and CaMKIV in normal and LN kidney specimens by immunofluorescence staining. We cultured human podocytes with IgG purified from sera of normal individuals and LN patient for 24 hr and analyzed CaMKIV mRNA levels by real time PCR. We also performed microarray analysis to determine gene expression.

Results: Although the expression levels of nephrin were decreased, CaMKIV expression was found increased in podocytes of LN kidney biopsy specimens. The levels of nephrin and CaMKIV correlated in an inverse manner.  Interestingly, culture of AB8/13 podocytes in the presence of IgG from LN sera led to 1.5-fold increase in the expression of CaMKIV mRNA.  Gene array analysis revealed that the expression of genes related to the cell activation including CaMKIV increased significantly (P<0.05) and the regulation of neural precursor cell proliferation decreased significantly (P<0.01) in podocytes treated with IgG from LN patients.

Conclusion: Our data demonstrate increased expression of CaMKIV in LN podocytes which may represent the result of exposure to IgG.  We suspect that increased CaMKIV expression may contribute to the inability of podocytes to maintain the integrity of glomerular basement membrane in LN patients. 

 


Disclosure:

K. Ichinose,
None;

T. Ushigusa,
None;

T. Koga,
None;

G. C. Tsokos,
None;

A. Kawakami,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/role-of-calciumcalmodulin-kinase-iv-on-podocyte-function-in-lupus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology